Infants' rapid weight gain risks adult obesity

In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.

A national claims analysis found 16.8% of pediatric GLP-1 users developed a nutritional deficiency within a year, most often vitamin D, while few received nutritional counseling.